ASCIMIB 40 mg (Asciminib): Uses, Dosage, Side Effects & CML Treatment
ASCIMIB 40 mg (Asciminib): Uses, Dosage, Side Effects & CML Treatment
ASCIMIB 40 mg contains asciminib, an oral targeted anticancer medicine used for specific adults with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP). Asciminib is a targeted tyrosine kinase inhibitor that works differently from conventional BCR::ABL1 inhibitors by binding to a specific site on the BCR::ABL1 protein known as the myristoyl pocket.
The supplied product list identifies ASCIMIB 40 MG as containing asciminib with a pack size of 30 tablets.
CML is a blood cancer associated with the BCR::ABL1 tyrosine kinase, which is produced as a result of the Philadelphia chromosome. This abnormal signalling protein promotes the growth and survival of malignant white blood cells.
Asciminib is designed to inhibit this disease-driving protein through an alternative binding mechanism. It is therefore considered a STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor.
Treatment should be started and monitored by a physician experienced in diagnosing and treating leukemia.
What Is ASCIMIB 40 mg?
ASCIMIB 40 mg is a tablet formulation containing asciminib, a targeted medicine for certain adults with Ph+ CML.
The product details provided are:
- Product Name: ASCIMIB 40 MG
- Generic Name: Asciminib
- Strength: 40 mg
- Dosage Form: Tablets
- Pack Size: 30 Tablets
Asciminib differs from many earlier tyrosine kinase inhibitors because it does not primarily bind to the ATP-binding site of BCR::ABL1. Instead, it binds to the myristoyl pocket of the ABL portion of the protein.
This distinctive mechanism is particularly relevant in the development of targeted treatment strategies for CML.
What Is Asciminib Used For?
Asciminib is used in adults with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP) under approved treatment conditions.
The EMA currently lists asciminib for:
- Adults with Ph+ CML in chronic phase.
- Adults with Ph+ CML-CP carrying the T315I mutation who are resistant to, intolerant of, or ineligible for ponatinib.
The precise indication and treatment setting can vary according to the regulatory authority and country.
Patient-Friendly Explanation
Asciminib is a targeted medicine for a particular type of leukemia called chronic myeloid leukemia.
It works by blocking an abnormal protein that helps leukemia cells grow.
Medical Explanation
Asciminib is a BCR::ABL1 tyrosine kinase inhibitor that specifically targets the ABL myristoyl pocket. This produces inhibition of BCR::ABL1 signalling and interferes with cellular processes required for malignant cell growth.
How Does Asciminib Work?
The underlying biology of Ph+ CML involves formation of the Philadelphia chromosome, which results from a genetic rearrangement involving chromosomes 9 and 22.
This rearrangement creates the BCR::ABL1 fusion gene, which produces an abnormal tyrosine kinase.
A simplified disease pathway is:
Philadelphia chromosome → BCR::ABL1 fusion gene → abnormal BCR::ABL1 kinase → uncontrolled signalling → abnormal white blood-cell growth
Asciminib works by targeting the myristoyl pocket of ABL.
Unlike many conventional BCR::ABL1 tyrosine kinase inhibitors that bind the ATP-binding site, asciminib binds to this separate regulatory pocket. This allows it to inhibit BCR::ABL1 activity through a different molecular mechanism.
The therapeutic concept can be represented as:
Asciminib → ABL myristoyl-pocket binding → BCR::ABL1 inhibition → reduced leukemia-cell signalling → suppression of malignant cell growth
This unique mechanism is why asciminib is often described as a STAMP inhibitor.
The medicine's ability to target BCR::ABL1 through a different binding site also makes it an important treatment option in certain patients whose disease has developed resistance or intolerance to previous tyrosine kinase inhibitor therapy.
However, treatment selection depends on disease phase, molecular findings, previous therapies, treatment response, tolerability and other clinical factors.
Key Indications
Philadelphia Chromosome-Positive CML
Asciminib is used in eligible adults with Ph+ CML in the chronic phase.
Patient-friendly:
The medicine targets the abnormal BCR::ABL1 protein responsible for driving the leukemia.
Medical:
Asciminib inhibits BCR::ABL1 signalling through binding to the ABL myristoyl pocket.
CML With T315I Mutation
Asciminib also has a specific indication for adults with Ph+ CML-CP carrying the T315I mutation when they are resistant to, intolerant of, or ineligible for ponatinib, according to EMA information.
The T315I mutation can significantly affect sensitivity to several BCR::ABL1-targeted medicines, making treatment selection particularly important.
Asciminib Dosage and Administration
The appropriate dose should always be determined by the treating hematologist or oncologist.
According to current EMA product information, the recommended regimen for Ph+ CML-CP without the T315I mutation is:
80 mg once daily OR 40 mg twice daily.
For patients with the T315I mutation, the recommended dose is higher and requires specialist supervision. The current product information specifies 200 mg twice daily for this indication.
Therefore, a 40 mg tablet does not automatically mean that every patient should take one tablet twice daily. The correct regimen depends on the clinical indication and prescribing instructions.
Administration Guidance
- Take asciminib exactly as prescribed.
- Follow the prescribed dosing schedule consistently.
- Tablets should be swallowed whole with water.
- Asciminib may be taken with or without food, depending on the applicable prescribing information.
- Do not independently increase or decrease the dose.
- Treatment should be monitored by a physician experienced in leukemia care.
Missed Dose
If a dose is missed, follow the instructions supplied with the specific product or contact the treating healthcare professional.
Do not automatically double the next dose unless specifically instructed.
Asciminib Side Effects
As with other anticancer medicines, asciminib can cause adverse reactions. The frequency and severity may vary between patients.
Common Side Effects
Reported adverse effects include:
- Musculoskeletal pain
- Thrombocytopenia
- Fatigue
- Upper respiratory tract infections
- Headache
- Neutropenia
- Joint pain
- Diarrhea
These are among the commonly reported adverse reactions in current EMA information.
Less Common Side Effects
Other reactions may include:
- Nausea
- Vomiting
- Cough
- Increased liver enzymes
- Increased pancreatic enzymes
- Abdominal discomfort
- Skin reactions
The adverse-effect profile can differ according to dose and treatment setting.
Serious Side Effects
Potential serious reactions include:
- Pancreatitis
- Pleural effusion
- Lower respiratory tract infection
- Significant thrombocytopenia
- Fever
- Pancreatic enzyme abnormalities
- Hepatic enzyme abnormalities
Some serious reactions are particularly relevant when asciminib is used at higher doses for T315I-mutated disease.
When to Seek Medical Attention
Prompt medical evaluation may be required for:
- Severe abdominal pain
- Persistent vomiting
- Difficulty breathing
- New or worsening cough
- Fever
- Unusual bleeding or bruising
- Severe weakness
- Yellowing of the skin or eyes
- Symptoms of infection
Drug Interactions
Asciminib can interact with other medicines. Patients should provide their healthcare professional with a complete list of prescription medicines, non-prescription products, vitamins and supplements.
Medicines Requiring Monitoring
Particular attention may be needed with medicines that:
- Affect CYP3A metabolism
- Affect CYP3A substrates
- Alter drug exposure
- Prolong the QT interval
- Affect cardiac rhythm
The treating physician should review concomitant medicines before treatment.
Food Considerations
Asciminib may be taken with or without food according to the applicable product information.
Patients should follow the instructions supplied with their specific product and prescription.
Supplement Considerations
Discuss the use of:
- Herbal products
- St John's wort
- Traditional medicines
- High-dose supplements
- Unregulated cancer products
with a healthcare professional before starting or during asciminib treatment.
Warnings and Precautions
Blood Count Monitoring
Asciminib may cause reductions in blood-cell counts, including thrombocytopenia and neutropenia.
Regular blood tests may therefore be required.
Pancreatic Considerations
Asciminib can increase pancreatic enzymes and may be associated with pancreatitis.
Severe or persistent abdominal pain should be reported promptly.
Liver Considerations
Liver enzyme elevations can occur during treatment.
Patients may require periodic liver-function monitoring.
Cardiovascular Considerations
Asciminib may require particular caution in patients with cardiovascular risk factors or medicines that can affect cardiac rhythm.
Healthcare professionals should review relevant cardiac risk factors and concomitant medicines.
Infection Risk
Patients receiving anticancer therapy can be vulnerable to infections, particularly when blood counts are affected.
Persistent fever or other signs of infection should be medically assessed.
Pregnancy and Breastfeeding
Asciminib should only be used during pregnancy when specifically considered appropriate by the treating healthcare professional.
Patients who may become pregnant should discuss contraception and pregnancy planning with their oncology team before treatment.
Breastfeeding should be discussed with a healthcare professional. Patients should follow the applicable product information regarding breastfeeding during therapy.
Special Populations
Elderly Patients
Older adults may receive asciminib when clinically appropriate. Treatment decisions should consider overall health, concurrent medicines, organ function and treatment tolerance.
Pediatric Patients
Asciminib is not automatically interchangeable between adult and pediatric treatment. Pediatric use should follow approved indications and specialist hematology/oncology guidance.
Renal Impairment
Patients with impaired kidney function should inform their physician before starting treatment. The treating specialist can determine appropriate monitoring and dosing.
Hepatic Impairment
Liver function is clinically relevant during asciminib treatment because liver-enzyme abnormalities may occur.
Patients with hepatic impairment should be evaluated individually by their treating healthcare professional.
Storage of ASCIMIB 40 mg
Store ASCIMIB 40 mg according to the instructions provided on the product packaging.
General precautions include:
- Keep tablets in the original packaging.
- Protect the medicine from unsuitable environmental conditions.
- Keep out of reach of children.
- Do not use damaged or visibly abnormal tablets.
- Follow the specific storage temperature stated on the product label.
Frequently Asked Questions About ASCIMIB 40 mg
1. What is ASCIMIB 40 mg used for?
ASCIMIB 40 mg contains asciminib and is used for eligible adults with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
2. What is asciminib?
Asciminib is a targeted BCR::ABL1 inhibitor that binds to the ABL myristoyl pocket.
3. Is asciminib a chemotherapy drug?
Asciminib is a targeted tyrosine kinase inhibitor rather than conventional cytotoxic chemotherapy.
4. How does asciminib work?
It binds to the myristoyl pocket of ABL and inhibits BCR::ABL1 signalling involved in CML-cell growth.
5. What is the usual asciminib dose?
For Ph+ CML-CP without T315I, current EMA information lists 80 mg once daily or 40 mg twice daily.
6. Can asciminib be taken with food?
Asciminib can be administered according to the food instructions in the applicable product information.
7. What are common asciminib side effects?
Common effects include musculoskeletal pain, low platelet counts, fatigue, upper respiratory infections, headache, neutropenia, joint pain and diarrhea.
8. Can asciminib cause low platelets?
Yes. Thrombocytopenia is a recognized adverse effect and blood-count monitoring may be required.
9. Can asciminib cause pancreatitis?
Pancreatitis is a potential serious adverse reaction. Severe abdominal pain should be medically evaluated.
10. What is the T315I mutation?
T315I is a mutation in BCR::ABL1 that can affect the response to several tyrosine kinase inhibitors.
11. Is asciminib used for chronic myeloid leukemia?
Yes. Asciminib is indicated for adults with Ph+ CML in the chronic phase in approved treatment settings.
12. Is asciminib a BCR::ABL1 inhibitor?
Yes. Asciminib specifically inhibits BCR::ABL1 through the ABL myristoyl pocket.
13. What makes asciminib different from other TKIs?
Asciminib targets the ABL myristoyl pocket, providing a different mechanism from ATP-site BCR::ABL1 inhibitors.
14. Can asciminib cause liver problems?
Liver enzyme elevations can occur, so liver-function monitoring may be required.
15. Can asciminib cure CML?
It should not be described as a guaranteed cure. It is a targeted treatment intended to control Ph+ CML in appropriate patients.
Global Medicine Information & Support by RootAid Pharma
RootAid Pharma provides pharmaceutical information and specialty-medicine support for individuals and organizations seeking information about prescription and high-value medicines.
Our information resources help international visitors understand:
- Generic and brand medicine information
- Therapeutic classes
- Oncology and hematology medicines
- Treatment indications
- Dosage information
- Safety considerations
- Drug interactions
- Specialty medicine information
- Prescription-related support
- International medicine supply information
For medicines such as asciminib, treatment should be managed by a qualified hematologist or oncologist.
RootAid Pharma can provide medicine-related information and supply assistance where legally and operationally applicable. Availability, prescription requirements, import regulations and local medicine rules may vary by country.
RootAid Pharma does not replace a physician, hematologist, oncologist or pharmacist and does not claim to manufacture ASCIMIB or asciminib.
Suggested Internal Links
- Oncology Medicines
- Hematology Medicines
- Leukemia Medicines
- Chronic Myeloid Leukemia Treatments
- Targeted Cancer Medicines
- Tyrosine Kinase Inhibitors
- Prescription Support
- Upload Prescription
- Global Medicine Information
- Contact RootAid Pharma
Medical Disclaimer
This article is intended for general educational and informational purposes only. It does not replace professional medical advice, diagnosis, prescribing information or individualized treatment planning.
Asciminib is a prescription anticancer medicine intended for specific patients with appropriate medical indications. Dose, treatment duration, monitoring, dose adjustments and treatment combinations must be determined by a qualified healthcare professional.
Approved indications and prescribing recommendations may vary between countries and may change as regulatory information is updated. Patients should consult the official product information applicable to their country and follow their healthcare professional's instructions.
Do not start, stop, increase or reduce asciminib without medical advice.
Need help after reading this?
Talk to our support team for sourcing guidance, product availability, and global delivery assistance.